Naval Daver, MD, from MD Anderson Cancer Center, shares results from a phase I/II study evaluating the addition of the anti-CD47 antibody magrolimab to standard azacitidine and venetoclax treatment in higher-risk acute myeloid leukemia.
Naval Daver on Adding Magrolimab to AML Backbone Treatment
By Naval Daver, MD - Last Updated: February 2, 2023Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.